Parkside Advisors LLC Has $542,000 Position in Johnson & Johnson (NYSE:JNJ)

Parkside Advisors LLC reduced its holdings in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 2.4% during the 2nd quarter, Holdings Channel.com reports. The fund owned 3,054 shares of the company’s stock after selling 74 shares during the period. Parkside Advisors LLC’s holdings in Johnson & Johnson were worth $542,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Family CFO Inc acquired a new position in Johnson & Johnson in the fourth quarter valued at about $26,000. RE Dickinson Investment Advisors LLC boosted its position in Johnson & Johnson by 163.3% in the first quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock valued at $28,000 after buying an additional 98 shares in the last quarter. Advanced Research Investment Solutions LLC boosted its position in Johnson & Johnson by 200.0% in the first quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock valued at $32,000 after buying an additional 120 shares in the last quarter. Professional Financial Advisors LLC boosted its position in Johnson & Johnson by 47.9% in the first quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock valued at $37,000 after buying an additional 68 shares in the last quarter. Finally, Joseph P. Lucia & Associates LLC acquired a new position in Johnson & Johnson in the first quarter valued at about $38,000. 68.59% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Trading Down 1.0 %

JNJ opened at $163.28 on Thursday. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.42 and a quick ratio of 1.17. The company has a market cap of $429.29 billion, a price-to-earnings ratio of 23.77, a price-to-earnings-growth ratio of 2.97 and a beta of 0.61. The firm has a 50 day simple moving average of $168.25 and a 200 day simple moving average of $174.16. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its earnings results on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The firm had revenue of $24.02 billion during the quarter, compared to the consensus estimate of $23.85 billion. During the same quarter in the prior year, the firm earned $2.48 earnings per share. The business’s quarterly revenue was up 3.0% on a year-over-year basis. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.7 earnings per share for the current year.

Johnson & Johnson announced that its Board of Directors has initiated a stock buyback program on Wednesday, September 14th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the company to buy up to 1.2% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s leadership believes its shares are undervalued.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd were paid a $1.13 dividend. This represents a $4.52 annualized dividend and a yield of 2.77%. The ex-dividend date was Monday, August 22nd. Johnson & Johnson’s payout ratio is presently 65.79%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on JNJ shares. Morgan Stanley reduced their target price on shares of Johnson & Johnson from $174.00 to $173.00 and set an “equal weight” rating on the stock in a research report on Monday, September 12th. Daiwa Capital Markets started coverage on shares of Johnson & Johnson in a research report on Wednesday, June 22nd. They set an “outperform” rating on the stock. SVB Leerink reduced their target price on shares of Johnson & Johnson from $200.00 to $194.00 in a research report on Wednesday, July 20th. UBS Group reduced their target price on shares of Johnson & Johnson from $185.00 to $180.00 in a research report on Thursday, July 21st. Finally, Citigroup reduced their target price on shares of Johnson & Johnson from $205.00 to $201.00 in a research report on Wednesday, July 20th. Four research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $189.78.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.